Free Trial
NASDAQ:INMD

InMode Q2 2025 Earnings Report

InMode logo
$14.10 -0.16 (-1.12%)
Closing price 04:00 PM Eastern
Extended Trading
$14.12 +0.02 (+0.11%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMode EPS Results

Actual EPS
N/A
Consensus EPS
$0.50
Beat/Miss
N/A
One Year Ago EPS
N/A

InMode Revenue Results

Actual Revenue
N/A
Expected Revenue
$98.45 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

InMode Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

InMode Earnings Headlines

Canaccord Genuity Maintains a Hold Rating on InMode Ltd. (INMD)
Analysts Set InMode Ltd. (NASDAQ:INMD) PT at $18.54
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
InMode's (INMD) "Hold" Rating Reiterated at Canaccord Genuity Group
See More InMode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InMode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMode and other key companies, straight to your email.

About InMode

InMode (NASDAQ:INMD) develops, manufactures and markets a broad range of medical aesthetic devices that leverage energy‐based technologies to deliver minimally invasive and noninvasive treatments. Its solutions employ radiofrequency, light and ultrasound to address skin tightening, body contouring, facial rejuvenation and various surgical applications. The company’s product portfolio includes platforms such as BodyTite, FaceTite and Morpheus8, which are designed to promote tissue coagulation, contraction and remodeling with reduced downtime compared to traditional surgical procedures.

Founded in 2008 in Israel by Dr. Moshe Mizrahy, InMode has grown from a single energy‐based technology venture into a publicly traded entity, listing on the NASDAQ in 2019 under the ticker INMD. Over the years, the company has expanded its global footprint, establishing direct sales operations and distribution partnerships across North America, Europe, Asia Pacific and Latin America. InMode’s solutions are cleared by key regulatory bodies, including the U.S. Food and Drug Administration and the European CE marking process, supporting a presence in more than 90 countries worldwide.

InMode’s devices are utilized by dermatologists, plastic surgeons and medical professionals for a range of aesthetic and clinical procedures. Beyond core face and body applications, the company offers specialized systems such as Evolve for hands‐free body remodeling and Optimas, a multi‐application platform that integrates treatments like Fractora, Lumecca and AccuTite. This modular approach allows practitioners to tailor procedures, optimizing patient outcomes while streamlining clinic workflows.

Leadership at InMode is led by founder and Chief Executive Officer Dr. Moshe Mizrahy, who brings extensive experience in RF and surgical technologies. The executive team emphasizes research and development, dedicating a significant portion of revenue to the advancement of next‐generation energy devices. By focusing on innovation, safety and ease of use, InMode aims to drive adoption of minimally invasive treatments and maintain its position as a leader in the rapidly evolving medical aesthetics market.

View InMode Profile

More Earnings Resources from MarketBeat